 |
Prospector
Profile
07.1168
|
| |
| Combimatrix Corporation |
NAICS |
541710 |
| 6500 Harbour Heights Parkway, Suite 303
Mukilteo, WA 98275 |
Description |
Biotechnology |
| (425) 493-2000 |
Employees |
59 |
| http://www.combimatrix.com/ |
Revenue |
(mil) |
8.0330 |
| |
Income |
(mil) |
-12.0410 |
| |
Assets |
(mil) |
52.5930 |
| |
Liability |
(mil) |
7.4950 |
| |
(for the year ended 2005-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Combimatrix Corporation reported a net loss of $3,567,000 for the three months ended June 30, 2007, higher than the net loss during the same period last year of $3,442,000. The Company also used cash for operating activities of $6,890,000 for the second quarter of 2007, compared to $8,095,000 during the same quarter a year ago. As a result of its recurring losses, the Company's balance sheet at June 30, 2007 showed $150,252,000 in accumulated deficit.
|
| |
|
Intellectual Property:
The Company currently has 5 patents issued in the United States, 3 patents issued in Europe and 87 patent applications pending in the United States, Europe and elsewhere. The patents covering its core technology begin to expire January 5, 2018. It also relies upon trade secret protection of confidential and proprietary information. [SEC Filing S-1 12-26-06]
|
| |
|
Description:
The Company engages in the development of technologies, and products and services in the areas of drug development, genetic analysis, nanotechnology research, defense, and homeland security markets.
|
| |
|
Officers:
Amit Kumar, Ph.D (Chair, Pres., CEO & Dir.); Brooke Anderson, Ph.D (COO & Dir.); Scott Burell, CPA (CFO, Sec. & Treas.); Andrew McShea, Ph.D (VP); Michael Tognotti (VP); Thomas Akin (Dir.); Rigdon Currie (Dir.); John Abeles, MD (Dir.)
|
| |
|
Auditor:
PricewaterhouseCoopers LLP
|
| |
|
Securities:
Common Stock-Symbol CBMX; NasdaqGM;
59,875,769 common shares outstanding as of July 27, 2007.
|
| |
| |
| |
| return to main page |
|
|
